Stay updated with breaking news from Pharma Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketPHAXIAM remains listed on Eu...
Investegate announcements from PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Investegate announcements from PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
Approval of study design by French ANSM and Ethics Committee Recruitment of 12 patients expected to start in Q4 2023 in 4 French centersFirst study results expected in mid-2024 Lyon (France) et Cambridge (MA, US),
Investegate announcements from PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus